APA (7th ed.) Citation

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, . . . Sychev DA. (2018). Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Dove Medical Press.

Chicago Style (17th ed.) Citation

Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, and Sychev DA. Effects of CYP2D6 Genetic Polymorphisms on the Efficacy and Safety of Fluvoxamine in Patients with Depressive Disorder and Comorbid Alcohol Use Disorder. Dove Medical Press, 2018.

MLA (9th ed.) Citation

Zastrozhin MS, et al. Effects of CYP2D6 Genetic Polymorphisms on the Efficacy and Safety of Fluvoxamine in Patients with Depressive Disorder and Comorbid Alcohol Use Disorder. Dove Medical Press, 2018.